ATE401057T1 - Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen - Google Patents
Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellenInfo
- Publication number
- ATE401057T1 ATE401057T1 AT05807394T AT05807394T ATE401057T1 AT E401057 T1 ATE401057 T1 AT E401057T1 AT 05807394 T AT05807394 T AT 05807394T AT 05807394 T AT05807394 T AT 05807394T AT E401057 T1 ATE401057 T1 AT E401057T1
- Authority
- AT
- Austria
- Prior art keywords
- lipid
- linked moiety
- microwaves
- introducing
- assembly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61750504P | 2004-10-08 | 2004-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401057T1 true ATE401057T1 (de) | 2008-08-15 |
Family
ID=35617473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05807394T ATE401057T1 (de) | 2004-10-08 | 2005-10-07 | Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7985417B2 (de) |
| EP (1) | EP1809246B1 (de) |
| JP (1) | JP2008515929A (de) |
| AT (1) | ATE401057T1 (de) |
| AU (1) | AU2005295072A1 (de) |
| CA (1) | CA2582242A1 (de) |
| DE (1) | DE602005008270D1 (de) |
| WO (1) | WO2006042270A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004096140A2 (en) | 2003-04-25 | 2004-11-11 | The Penn State Research Foundation | Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| WO2008120998A2 (en) * | 2007-03-30 | 2008-10-09 | Epitarget As | Acoustically sensitive drug delivery particles |
| MX2010003536A (es) | 2007-10-02 | 2010-04-27 | Kuhs Gmbh | Composicion cosmetica o farmaceutica para aplicacion topica. |
| US9078812B2 (en) | 2007-12-06 | 2015-07-14 | The Bay Zoltan Foundation For Applied Research | Particulate drug carriers as desensitizing agents |
| AU2010270722B2 (en) * | 2009-07-06 | 2015-06-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| JP2013529638A (ja) * | 2010-06-19 | 2013-07-22 | ウェスタン ユニバーシティ オブ ヘルス サイエンス | Peg化リポソーム封入糖ペプチド抗生物質の新規製剤 |
| MX342138B (es) | 2010-07-06 | 2016-09-14 | Variation Biotechnologies Inc | Composiciones y metodos para el tratamiento de influenza. |
| CA2862864C (en) | 2011-01-13 | 2018-12-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| WO2013047263A1 (ja) * | 2011-09-28 | 2013-04-04 | テルモ株式会社 | ヘモグロビン含有リポソーム及びその製法 |
| US20140356399A1 (en) | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| CN105188675A (zh) * | 2013-03-13 | 2015-12-23 | 马林克罗特有限公司 | 经修饰多西他赛脂质体制剂 |
| GB201612108D0 (en) | 2016-07-12 | 2016-08-24 | Univ Strathclyde | Preperation of non-ionic surfactant vesicles and variants |
| PL3811931T3 (pl) | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| WO2020071349A1 (ja) * | 2018-10-01 | 2020-04-09 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IS1685B (is) * | 1990-12-11 | 1998-02-24 | Bracco International B.V. | Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| US6180134B1 (en) | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
| SE9403245D0 (sv) | 1994-09-26 | 1994-09-26 | Pharmacia Biosensor Ab | Improvements relating to bilayer lipid membranes |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5616790A (en) | 1994-11-18 | 1997-04-01 | California Institute Of Technology | Lipid-based metal sensor |
| TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| EP0941474B1 (de) | 1996-11-29 | 2006-03-29 | The Board Of Trustees Of The Leland Stanford Junior University | Anordnungen von unabhängig voneinander ansteuerbaren, gestützten flüssigbilayer-membranen und ihre anwendungsverfahren |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| WO2001026800A1 (en) | 1999-10-08 | 2001-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Lipid-bilayer arrays and methods of making and using same |
-
2005
- 2005-10-07 AT AT05807394T patent/ATE401057T1/de not_active IP Right Cessation
- 2005-10-07 JP JP2007535913A patent/JP2008515929A/ja active Pending
- 2005-10-07 AU AU2005295072A patent/AU2005295072A1/en not_active Abandoned
- 2005-10-07 US US11/246,340 patent/US7985417B2/en not_active Expired - Fee Related
- 2005-10-07 EP EP05807394A patent/EP1809246B1/de not_active Expired - Lifetime
- 2005-10-07 DE DE602005008270T patent/DE602005008270D1/de not_active Expired - Lifetime
- 2005-10-07 WO PCT/US2005/036646 patent/WO2006042270A1/en not_active Ceased
- 2005-10-07 CA CA002582242A patent/CA2582242A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005008270D1 (de) | 2008-08-28 |
| CA2582242A1 (en) | 2006-04-20 |
| US7985417B2 (en) | 2011-07-26 |
| EP1809246A1 (de) | 2007-07-25 |
| WO2006042270A1 (en) | 2006-04-20 |
| EP1809246B1 (de) | 2008-07-16 |
| US20060121105A1 (en) | 2006-06-08 |
| AU2005295072A1 (en) | 2006-04-20 |
| JP2008515929A (ja) | 2008-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401057T1 (de) | Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen | |
| Cheng et al. | Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency | |
| BR0113477A (pt) | Peptìdios de penetração em membranas e usos dos mesmos | |
| PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| DE69616523D1 (de) | Verfahren zur baladung von lipidvesikeln | |
| CY1118629T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
| AR037666A1 (es) | Metodo para la identificacion de enzimas marcadores tumorales | |
| EP1874793A4 (de) | Abgabe von sirna durch neutrale lipid-zusammensetzungen | |
| ATE200679T1 (de) | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen | |
| BRPI0414128A (pt) | sistema e método para aumento de mamas | |
| BRPI0915142A8 (pt) | Polipeptídeos, ácido nucleico e usos dos mesmos | |
| ES2185705T3 (es) | Proteina bifuncional, preparacion y uso. | |
| ES2534303T3 (es) | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN | |
| BRPI0415308A (pt) | incorporação especìfica de local de aminoácidos redox ativos em proteìnas | |
| DK1633784T3 (da) | OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder | |
| BR9914476A (pt) | Preparados dérmicos para uso externo | |
| ATE453328T1 (de) | Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials | |
| BR0109958A (pt) | Análogos de didemnina e tamandarina e métodos de preparação e uso deles | |
| Brogden et al. | Isolation and analysis of membrane lipids and lipid rafts in common carp (Cyprinus carpio L.) | |
| PT1274399E (pt) | Liposomas que contem um componente envolvente numa solucao supersaturada | |
| WO2005112546A3 (en) | Mucinous glycoprotein (muc-1) vaccine | |
| Sonaje et al. | Iontosomes: electroresponsive liposomes for topical iontophoretic delivery of chemotherapeutics to the buccal mucosa | |
| AU4850601A (en) | Protein stabilised emulsions | |
| WO2009059201A3 (en) | Id2 as a target in colorectal carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |